TCM
BPMC

TD Capital Management’s Blueprint Medicines BPMC Stock Holding History

TD Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed -$12.8K – 696
2025
Q2 		$12.8K Hold
100
– – ﹤0.01% 386
2025
Q1 		$8.85K Buy
+100
New +$9.76K ﹤0.01% 320
2023
Q3 		– Sell
-130
Closed -$8.22K – 414
2023
Q2 		$8.22K Hold
130
– – ﹤0.01% 291
2023
Q1 		$5.85K Buy
+130
New +$5.86K ﹤0.01% 312

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

TD Capital Management's BPMC Position: Q3 2025 in Review

TD Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 100 shares — an estimated $12.8K sold.

TD Capital Management first reported a position in BPMC in Q1 2023 and held it in 4 quarters. The position peaked at $12.8K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • TD Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • TD Capital Management sold 100 Blueprint Medicines shares in Q3 2025, an estimated $12.8K.
  • TD Capital Management first reported a position in Blueprint Medicines in Q1 2023 and held it in 4 quarters.
  • TD Capital Management's Blueprint Medicines position peaked at $12.8K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on TD Capital Management's 13F filing for Q3 2025, filed 24 Nov 2025.